You are here
Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience.
Session Type and Session Title:
General Poster Session, Melanoma/Skin Cancers
J Clin Oncol 30, 2012 (suppl; abstr 8549)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Ipilimumab (ipi) is an antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4) and improves overall survival in patients (pts) with metastatic melanoma. Uveal melanoma (UM) is a rare and biologically unique disease subtype with no known effective systemic therapy. Ipi has proven efficacy in cutaneous melanoma (CM), but limited data exists regarding its activity in UM. We reviewed our single-institutional experience with ipi in advanced UM. Methods: After IRB approval, the MSKCC melanoma database was queried for patients with metastatic UM treated with ipi between 03/08-01/12. Radiographic response by RECIST and immune-related response criteria (irRC) was assessed by a single radiologist blinded to clinical outcomes. Immune-related adverse events (irAEs), survival and absolute lymphocyte count (ALC) were also evaluated.
|Immune-related response criteria||12 wks||24 wks|
|Stable disease||7/20 (35%)||4/20 (20%)|
|Partial response||1/20 (5%)||1/20 (5%)|
|Clinical benefit||8/20 (40%)||5/20 (25%)|